Epicrispr Biotechnologies, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://www.epic-bio.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy
- First Posted Date
- 2025-04-02
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Epicrispr Biotechnologies, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT06907875
- Locations
- 🇦🇺
Royal Alfred Hospital, Sydney, New South Wales, Australia
🇺🇸Rare Disease Research, Atlanta, Georgia, United States
🇳🇿Pacific Clinical Research Network, Auckland, New Zealand
News
No news found